FDA sharps device requirements
This article was originally published in The Gray Sheet
FDA establishes interim policy that scales back clinical data requirements outlined in its draft guidance on sharps devices with injury prevention features. Under the interim policy, which will be in effect until FDA finalizes revisions to the draft, "a modicum" of in-use data will be required to demonstrate safety and effectiveness of the devices, FDAers say. The amount and type of data will depend upon the device's intended use. The clinical data provisions in the draft came under criticism at a May meeting of FDA's General Hospital and Restorative Devices Advisory Panel ("The Gray Sheet" May 16, I&W-1)
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.